CSL Behring Release: Humate-P(R) Approved to Prevent Excessive Bleeding in Patients with von Willebrand Disease Undergoing Surgery

KING OF PRUSSIA, Pa., April 30 /PRNewswire/ -- Humate-P® (Antihemophilic Factor/von Willebrand Factor Complex [Human]), CSL Behring's factor replacement therapy for the treatment of hemophilia A and von Willebrand disease (VWD), has been approved by the U.S. Food and Drug Administration (FDA) to prevent excessive bleeding during and after surgery, in patients with severe VWD and mild to moderate VWD where the use of desmopressin is known or suspected to be inadequate. The new indication approval follows the results of two separate clinical studies - one in Europe, another in the United States - that demonstrate the hemostatic efficacy and safety of Humate-P for VWD patients undergoing major, minor and oral surgical procedures.

Back to news